Journal ArticleDOI
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
TLDR
As high levels of low- density lipoprotein particles are a robust predictor of cardiovascular events, strategies targeted at raising low levels of high-densitylipoprotein cholesterol must account for low-density lipop protein particle interactions.Abstract:
Purpose of review Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels. Recent findings Low high-density lipoprotein cholesterol levels are commonly encountered among patients with early onset cardiovascular disease. Most often, a low high-density lipoprotein cholesterol level is not an isolated abnormality, but it is usually associated with a number of other lipoprotein abnormalities. Data from the Framingham Offspring Study demonstrate that among subjects with high-density lipoprotein cholesterol, 1.0 mmol/L (39 mg/dL), low-density lipoprotein particle numbers were considerably higher than indicated by the level of low-density lipoprotein cholesterol because these subjects had excess numbers of small cholesterol-depleted low-density lipoprotein particles. Elevated numbers of low-density lipoprotein particles identify individuals at highest risk for atherosclerotic vascular disease and cardiovascular events. Summary As high levels of low-density lipoprotein particles are a robust predictor of cardiovascular events, strategies targeted at raising low levels of high-density lipoprotein cholesterol must account for low-density lipoprotein particle interactions.read more
Citations
More filters
Journal ArticleDOI
Modulation of fatty acid transport and metabolism by maternal obesity in the human full-term placenta.
Evemie Dubé,Ariane Gravel,Coralie Martin,Guillaume Desparois,Issa Moussa,Maude Ethier-Chiasson,Jean-Claude Forest,Yves Giguère,André Masse,Julie Lafond +9 more
TL;DR: Overall this study demonstrated that maternal obesity impacts placental FA uptake without affecting fetal growth, however, these changes could modify the fetus metabolism and its predisposition to develop diseases later in life.
Journal ArticleDOI
Systematic Review, Meta-Analysis and Regression of Randomised Controlled Trials Reporting an Association Between an Intake of Circa 25 G Soya Protein Per Day and Blood Cholesterol
TL;DR: The inclusion of modest amounts soya protein into the diet of adults with normal or mild hypercholesterolaemia resulted in small, highly significant reductions in total and LDL cholesterol, equivalent to ca.
Journal ArticleDOI
Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
TL;DR: Results reveal for the first time that resistin is a highly attractive therapeutic target in ameliorating elevated serum low-density lipoprotein and, thereby, atherosclerotic cardiovascular diseases in obese humans.
Journal ArticleDOI
Cardiovascular risks in spondyloarthritides.
TL;DR: Novel findings regarding cardiac and vascular pathologies and potential overlapping mechanisms will be discussed, and the beneficial effects of statin treatment on circulating inflammatory mediators and atherogenic lipid profiles may reveal new therapeutic options for patients with spondyloarthritides.
Journal ArticleDOI
Subjects with elevated LDL cholesterol and metabolic syndrome benefit from supplementation with soy protein, phytosterols, hops rho iso-alpha acids, and Acacia nilotica proanthocyanidins
Robert Lerman,Deanna M. Minich,Gary Darland,Joseph J. Lamb,Jyh-Lurn Chang,Alex Hsi,Jeffrey S. Bland,Matthew L. Tripp +7 more
TL;DR: Individuals at high CVD risk benefit from a soy/phytosterol containing medical food and phytochemical supplemented lifestyle program.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
TL;DR: These results from a representative sample of US adults show that the metabolic syndrome is highly prevalent and the large numbers of US residents with the metabolic Syndrome may have important implications for the health care sector.
Journal ArticleDOI
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Hanna Bloomfield Rubins,Sander J. Robins,Dorothea Collins,Carol L. Fye,James W. Anderson,Marshall B. Elam,Fred H. Faas,Esteban Linares,Ernst J. Schaefer,Gordon Schectman,Timothy J Wilt,Janet Wittes +11 more
TL;DR: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Journal ArticleDOI
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
James Shepherd,Gerard J. Blauw,Michael B. Murphy,Edward L.E.M. Bollen,Brendan M. Buckley,Stuart M. Cobbe,Ian Ford,Allan Gaw,Michael E. Hyland,J. Wouter Jukema,Adriaan M. Kamper,Peter W. Macfarlane,A. Edo Meinders,John Norrie,Chris J. Packard,Ivan J. Perry,David J. Stott,Brian Sweeney,Gillian Twomey,Rudi G. J. Westendorp +19 more
TL;DR: Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals and was extended to elderly individuals the treatment strategy currently used in middle aged people.